The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

The erbB-2/HER2 oncogene is overexpressed in a significant fraction of human carcinomas of the breast, ovary, and lung in a manner that correlates with poor prognosis. Although the encoded protein resembles several receptors for growth factors, no high affinity ligand of ErbB-2 has so far been fully characterized. However, several lines of evidence have raised the possibility that ErbB-2 can augment signal transduction initiated by binding of certain growth factors to their direct receptors. Here, we contrasted these two models of ErbB-2 function: First, examination of a large series of epidermal growth factor (EGF)-like ligands and neuregulins, including virus-encoded ligands as well as related motifs derived from the precursor of EGF, failed to detect interactions with ErbB-2 when this protein was singly expressed. Second, by using antibodies that block inter-ErbB interactions and cells devoid of surface ErbB-2, we learned that signaling by all ligands examined, except those derived from the precursor of EGF, was enhanced by the oncoprotein. These results imply that ErbB-2 evolved as a shared receptor subunit of all ErbB-specific growth factors. Thus, oncogenicity of ErbB-2 in human epithelia may not rely on the existence of a specific ligand but rather on its ability to act as a coreceptor for multiple stroma-derived growth factors.

[1]  M. Eisenstein,et al.  Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.

[2]  D. Kohda,et al.  Structure of epidermal growth factor bound to perdeuterated dodecylphosphocholine micelles determined by two-dimensional NMR and simulated annealing calculations. , 1992, Biochemistry.

[3]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[4]  A. Burgess,et al.  Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .

[5]  Y. Yarden,et al.  An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.

[6]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[7]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[8]  B. Mroczkowski,et al.  Recombinant human epidermal growth factor precursor is a glycosylated membrane protein with biological activity , 1989, Molecular and Cellular Biology.

[9]  Y. Yarden,et al.  Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes* , 1998, The Journal of Biological Chemistry.

[10]  Y. Yarden,et al.  Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase , 1999, Oncogene.

[11]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[12]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[13]  P. Fedi,et al.  Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors , 1997, The EMBO journal.

[14]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[15]  J. Engel.  EGF‐like domains in extracellular matrix proteins: Localized signals for growth and differentiation? , 1989, FEBS letters.

[16]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[17]  M. Eisenstein,et al.  ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network , 1998, Molecular and Cellular Biology.

[18]  A. Lenferink,et al.  The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin , 1998, Oncogene.

[19]  M. Sliwkowski,et al.  Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[21]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[22]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[23]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[24]  N. Hynes,et al.  Intracellular expression of single chain antibodies reverts ErbB-2 transformation. , 1994, The Journal of biological chemistry.

[25]  Ling-mei Wang,et al.  ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Sternberg,et al.  Mutations in the Caenorhabditis elegans let‐23 EGFR‐like gene define elements important for cell‐type specificity and function. , 1994, The EMBO journal.

[27]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[28]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[29]  T. van Raaij,et al.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.

[30]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[31]  E. Peles,et al.  ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.

[32]  D. Stern,et al.  Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2* , 1998, The Journal of Biological Chemistry.

[33]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[34]  Y. Yarden,et al.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network , 1998, The EMBO journal.

[35]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[36]  H. Rubinfeld,et al.  Detection of ERK activation by a novel monoclonal antibody , 1997, FEBS letters.